# Nilo Therapeutics

> Nilo Therapeutics is a New York-based biotechnology company developing a new class of medicines that target the brain-body neural circuits regulating the immune system. Building on discoveries that identified specific vagal neurons controlling systemic inflammation, Nilo aims to restore immune homeostasis centrally rather than broadly suppress the immune system, offering a differentiated approach to treating autoimmune and inflammatory disease. The company launched out of stealth in October 2025 with a $101 million Series A.

- **Founded:** 2025
- **Headquarters:** New York, New York, United States
- **Founders:** Charles Zuker (Scientific Founder (Columbia University, HHMI Investigator)), Ruslan Medzhitov (Scientific Founder (Yale University)), Steve Liberles (Scientific Founder (Harvard University))
- **Team size:** ~35 employees
- **Products:** Neural circuit-based immunomodulation platform, Preclinical pipeline
- **Notable:** Launched out of stealth in October 2025 with a $101 million Series A., Assembled scientific founders from Columbia, Yale, and Harvard., Attracted top-tier investors including Lux Capital, DCVC Bio, The Column Group, the Gates Foundation, and Alexandria Venture Investments.

## Products & services

- **Neural circuit-based immunomodulation platform** — A drug discovery platform that targets master-regulator brain-body circuits - including specific vagal neurons - to centrally modulate multiple immune pathways in concert, reducing the risk of therapeutic resistance and broadening therapeutic impact across autoimmune and inflammatory disease.
- **Preclinical pipeline** — Early-stage programs aimed at autoimmune and inflammatory diseases with large unmet need. Specific disease indications have not been publicly disclosed; the company is in the preclinical stage.

## Achievements

- Launched out of stealth in October 2025 with a $101 million Series A.
- Assembled scientific founders from Columbia, Yale, and Harvard.
- Attracted top-tier investors including Lux Capital, DCVC Bio, The Column Group, the Gates Foundation, and Alexandria Venture Investments.
- Recruited Kim Seth, Ph.D. (former CBO of Repare Therapeutics) as CEO and Laurens Kruidenier, Ph.D. as CSO.

## Latest updates

- **2025-10** — Nilo Therapeutics launched out of stealth with a $101M Series A, appointed Kim Seth as CEO, and announced plans to build New York City laboratories, grow its R&D team, and advance preclinical programs.

## Links

- Website: https://nilotx.com
- LinkedIn: https://www.linkedin.com/company/nilo-therapeutics

---

Profile page: https://yespress.io/nilo-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-13